Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry

• Published in: Ophthalmology and therapy 2022-04, Vol.11 (2), p.797-810
• Main Authors: Bhandari, Sanjeeb, Gabrielle, Pierre-Henry, Nguyen, Vuong, Daien, Vincent, Viola, Francesco, Bougamha, Walid, Young, Stephanie, Romero-Nuñez, Barbara, Figueras-Roca, Marc, Zarranz-Ventura, Javier, Barthelmes, Daniel, Sararols, Laura, Gillies, Mark, Creuzot-Garcher, Catherine
• Format: Article
• Language: English
• Subjects: Human health and pathology; Internal Medicine; Life Sciences; Medicine; Medicine & Public Health; Ophthalmology; Original Research; Sensory Organs
• ISSN: 2193-8245; 2193-6528
• DOI: 10.1007/s40123-022-00473-3

Introduction Phase III clinical trials of dexamethasone intravitreal implant for diabetic macular oedema (DMO) have reported significant improvements in visual acuity (VA). Studies evaluating the treatment of DMO in routine clinical practice provide data to identify areas that need improvement. This study evaluated 12-month treatment outcomes of dexamethasone implant for DMO in routine clinical practice. Methods Retrospective data analysis of eyes that started dexamethasone implant for DMO from 1 June 2013 to 30 April 2019 in routine clinical practice tracked in the Fight Retinal Blindness! Registry. Results Of the 4282 eyes (2518 patients) that started DMO treatment in the specified period, 267 (6%) eyes (204 patients) received 454 dexamethasone implant injections. Two-fifths (106 eyes) had received prior treatment for DMO. The mean (95% confidence interval [CI]) VA change at 12 months was 1.8 (− 0.5, 4.2) letters from the mean (standard deviation [SD]) VA of 56.5 (19.8) letters at baseline, with 41% eyes achieving at least 20/40. The mean (95% CI) change in central subfield thickness over 1 year was − 79 (− 104, − 54) µm from a mean (SD) of 459 (120) µm at baseline. Eyes that completed 1 year of follow-up received a median (Q1, Q3) of 2 (1, 2) dexamethasone implants. One-tenth of phakic eyes received cataract surgery while 2% had a pressure response requiring anti-glaucoma medications. Conclusions One-year treatment outcomes of dexamethasone intravitreal implant for DMO in routine clinical practice were inferior to those in the clinical trials perhaps because of fewer treatments in clinical practice.